Pharvaris N.V.

Overview

Compare with another stock.

• TickerPHVS on Nasdaq¹
• IndustryPharmaceutical Preparations¹
• HeadquartersP7¹
• Incorporated inNetherlands³
• Business addressJ.H. Oortweg 21, 2333 Ch Leiden, Leiden³
• Filer categoryLarge accelerated filer³

See how the biggest companies compare on our leaderboards

We are a late-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases. Our first molecule, deucrictibant (previously referred to as PHA-022121 or PHA121), is a novel, oral, small-molecule bradykinin B2 receptor antagonist under development for the prevention or treatment of attacks due to bradykinin-mediated angioedema (AE-BK), including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH). Deucrictibant has the potential to address unmet medical needs by bringing improvements beyond the therapeutic profile of existing medicines and providing patients with quality of life and convenience that is superior to current standard-of-care. We believe deucrictibant has the potential to prov…⁴ From its latest annual report

Corporate structure

Pharvaris N.V. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Pharvaris N.V. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Leadership

Who has led Pharvaris N.V., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerBerndt Modig Mar 18, 2026 to now¹⁰
• PresidentPeng Lu Aug 13, 2026 to now¹¹
• Chief financial officerDavid W. Nassif Mar 18, 2026 to now¹²

Former names

• Pharvaris, B.V.Nov 12, 2020 to Feb 4, 2021³

Timeline

1. Mar 18, 2026New chief executive Berndt Modig becomes CEO¹⁰

Calendar

Coming up

1. Nov 11, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.70) a share, on Nov 12, 2025.²⁴

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

288 filings to the SEC since October 2021: 5 annual reports, 70 insider forms, 26 large holders, 187 other. The latest 20:

1. Oct 13, 20264 EDGAR
2. Sep 25, 20264 EDGAR
3. Sep 24, 20264 EDGAR
4. Sep 24, 20264 EDGAR
5. Sep 23, 2026144 EDGAR
6. Sep 23, 20264 EDGAR
7. Sep 22, 2026144/A EDGAR
8. Sep 22, 2026144 EDGAR
9. Sep 21, 2026144 EDGAR
10. Sep 21, 20264 EDGAR
11. Sep 21, 20264 EDGAR
12. Sep 21, 20264 EDGAR
13. Sep 21, 20264 EDGAR
14. Sep 21, 20264 EDGAR
15. Sep 21, 20264 EDGAR
16. Sep 17, 2026144 EDGAR
17. Sep 17, 2026144 EDGAR
18. Sep 17, 2026144 EDGAR
19. Sep 17, 2026144 EDGAR
20. Sep 17, 2026144 EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

54 open-market trades by officers, directors and large owners since October 2021: 0 buys and 54 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• GENERAL ATLANTIC, L.P.SCHEDULE 13G/A, 3 filings Jun 23, 2023 to Aug 14, 2026²⁵
• Cooperatieve U.a. Lsp V.SCHEDULE 13G/A, 3 filings Feb 3, 2022 to Jul 31, 2026²⁶
• VIKING GLOBAL INVESTORS LPSCHEDULE 13G/A, 4 filings Feb 14, 2022 to May 15, 2026²⁷
• Bain Capital Life Sciences Fund, L.P.SCHEDULE 13G/A, 4 filings Jun 23, 2023 to Feb 17, 2026²⁸
• Venrock Healthcare Capital Partners III, L.P.SCHEDULE 13G/A, 3 filings Nov 30, 2023 to Aug 14, 2025²⁹
• Foresite Capital Fund IV, L.P.SC 13G/A, 3 filings Feb 11, 2022 to Feb 13, 2024³⁰
• FMR LLCSC 13G/A, 3 filings Feb 9, 2022 to Feb 9, 2024³¹
• venBio Global Strategic Fund III, L.P.SC 13D/A, 3 filings Sep 26, 2022 to Jan 25, 2024³²

SEC filer profile

How Pharvaris N.V. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARPharvaris N.V.¹
• CIK0001830487
• Filer statusLarge accelerated filer not an emerging growth company; not a shell company⁴
• Incorporated inNetherlands⁴
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business addressJ.H. Oortweg 21, 2333 Ch Leiden, Leiden, Netherlands¹
• Phone31 (0)71 203 6410¹
• Shares outstanding65,210,590 shares as of Dec 31, 2025⁴
• AuditorPricewaterhouseCoopers Accountants N.V, Amsterdam, The Netherlands PCAOB ID 1395; it also attests to the company’s internal control over financial reporting⁴
• On EDGAR sinceNov 12, 2020¹
• Filings327 in all: 144 (94), 6-K (73), 4 (55), SC 13G/A (14), 3 (13), CORRESP (8), UPLOAD (8), SC 13G (7)¹
  All 33 form types

  20-F (6), 424B5 (6), SCHEDULE 13G/A (6), 144/A (4), EFFECT (3), SC 13D/A (3), 6-K/A (2), DRS/A (2), DRSLTR (2), F-1/A (2), F-3 (2), F-3ASR (2), FWP (2), SEC STAFF LETTER (2), 3/A (1), 4/A (1), 424B4 (1), 8-A12B (1), CERT (1), DRS (1), F-1 (1), F-1MEF (1), POSASR (1), S-8 (1), SC 13D (1)

• Latest filingsAnnual report (20-F) Apr 2, 2026

Securities registered for trading

From the cover page of the 20-F filed Apr 2, 2026 (Section 12(b) of the Exchange Act).⁴